JP2018064568A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018064568A5 JP2018064568A5 JP2017223489A JP2017223489A JP2018064568A5 JP 2018064568 A5 JP2018064568 A5 JP 2018064568A5 JP 2017223489 A JP2017223489 A JP 2017223489A JP 2017223489 A JP2017223489 A JP 2017223489A JP 2018064568 A5 JP2018064568 A5 JP 2018064568A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- truncated
- nucleic acid
- composition according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126804P | 2015-03-02 | 2015-03-02 | |
| US62/126,804 | 2015-03-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546893A Division JP6336684B2 (ja) | 2015-03-02 | 2016-03-01 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018064568A JP2018064568A (ja) | 2018-04-26 |
| JP2018064568A5 true JP2018064568A5 (enExample) | 2019-02-21 |
| JP6767347B2 JP6767347B2 (ja) | 2020-10-14 |
Family
ID=56848306
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546893A Active JP6336684B2 (ja) | 2015-03-02 | 2016-03-01 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
| JP2017223489A Active JP6767347B2 (ja) | 2015-03-02 | 2017-11-21 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546893A Active JP6336684B2 (ja) | 2015-03-02 | 2016-03-01 | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9572837B2 (enExample) |
| EP (2) | EP3549612B1 (enExample) |
| JP (2) | JP6336684B2 (enExample) |
| KR (1) | KR102133857B1 (enExample) |
| CN (2) | CN108410892B (enExample) |
| AU (1) | AU2016228080B2 (enExample) |
| BR (1) | BR112017018770A2 (enExample) |
| CA (1) | CA2976684C (enExample) |
| RU (1) | RU2688692C2 (enExample) |
| SG (1) | SG11201706947TA (enExample) |
| WO (1) | WO2016138846A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US10765699B2 (en) | 2015-02-06 | 2020-09-08 | National University Of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| KR102133857B1 (ko) | 2015-03-02 | 2020-07-20 | 이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드 | Ｐｄ－ｌ１에 의해 유도된 면역관용의 감소 |
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| US11242375B2 (en) | 2015-09-04 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| US11648268B2 (en) | 2015-12-09 | 2023-05-16 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| WO2017162797A1 (en) * | 2016-03-23 | 2017-09-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| US10654934B2 (en) | 2016-04-01 | 2020-05-19 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| EP3436059B1 (en) | 2016-04-01 | 2022-01-12 | Innovative Cellular Therapeutics Holdings, Ltd. | Use of chimeric antigen receptor modified cells to treat cancer |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018044866A1 (en) | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| WO2018064921A1 (en) * | 2016-10-06 | 2018-04-12 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| US11440958B2 (en) | 2016-11-22 | 2022-09-13 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CN108148862B (zh) * | 2016-12-05 | 2019-03-08 | 上海优卡迪生物医药科技有限公司 | 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用 |
| US20190358263A1 (en) | 2016-12-07 | 2019-11-28 | Oslo Universitetssykehus Hf | Compositions and Methods for Cell Therapy |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| CA3055539A1 (en) * | 2017-03-08 | 2018-09-13 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CN111247241A (zh) | 2017-08-10 | 2020-06-05 | 新加坡国立大学 | T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法 |
| AU2018339528A1 (en) * | 2017-09-26 | 2020-04-16 | Longwood University | PD1-specific chimeric antigen receptor as an immunotherapy |
| CN109836493A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向cd19的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| US10561686B2 (en) * | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| WO2019156795A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| EP3784776A4 (en) | 2018-05-23 | 2022-01-26 | National University of Singapore | Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US20210379149A1 (en) * | 2018-10-25 | 2021-12-09 | Innovative Cellular Therapeutics Holdings, Ltd. | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| WO2020116686A1 (ko) * | 2018-12-06 | 2020-06-11 | 고려대학교 산학협력단 | 인간 항-antxr 키메라 항원 수용체 및 이의 용도 |
| CN109971842A (zh) * | 2019-02-15 | 2019-07-05 | 成都美杰赛尔生物科技有限公司 | 一种检测CRISPR-Cas9脱靶效应的方法 |
| WO2020172555A1 (en) * | 2019-02-21 | 2020-08-27 | Regents Of The University Of Minnesota | Genetically modified gamma delta t cells and methods of making and using |
| AU2020232216B2 (en) * | 2019-03-01 | 2025-09-25 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| JP2022531814A (ja) * | 2019-03-12 | 2022-07-12 | イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ | 改変細胞の増幅およびその応用 |
| US11739136B2 (en) * | 2019-03-18 | 2023-08-29 | Innovative Cellular Therapeutics Holdings, Ltd. | Inducible dominant negative PD-1 and uses in adoptive cell therapy |
| CN109868263A (zh) * | 2019-03-29 | 2019-06-11 | 深圳精准医疗科技有限公司 | 重组单纯疱疹病毒及其制备方法和应用、重组载体的构建方法及其应用 |
| BR112021022795A2 (pt) * | 2019-05-16 | 2022-01-18 | Memorial Sloan Kettering Cancer Center | Composição polipeptídica compreendendo cars de mesotelina , células imunorresponsivas e seu método de produção, composição farmacêutica, composição de ácido nucleico, vetor e kit compreendendo composição de polipeptídeo |
| CN110423767A (zh) * | 2019-07-12 | 2019-11-08 | 华东师范大学 | 表达可溶性pd-1的嵌合抗原受体car基因及应用 |
| CN110592140A (zh) * | 2019-09-30 | 2019-12-20 | 王清路 | Pd-1基因缺陷型pd-1-cart细胞制剂的制法 |
| US20210137983A1 (en) * | 2019-11-08 | 2021-05-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Nk cell expansion and uses thereof |
| KR20250048487A (ko) * | 2019-11-26 | 2025-04-08 | 난트퀘스트, 인크. | 일차 nk car 구축물 및 방법 |
| KR20220163940A (ko) | 2020-02-04 | 2022-12-12 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 항-디니트로페놀 키메라 항원 수용체 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| JP7198302B2 (ja) * | 2021-03-08 | 2022-12-28 | 一般財団法人 化学物質評価研究機構 | Ｐｄ－１を介した免疫チェックポイント阻害剤の生物活性試験法 |
| US20230227779A1 (en) | 2022-01-19 | 2023-07-20 | Innovative Cellular Therapeutics Holdings, Ltd. | Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment |
| WO2025184170A1 (en) * | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| EP1425421A2 (en) * | 2001-09-07 | 2004-06-09 | Everygene AB | Polymorphisms of pd-1 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| PH12014500247A1 (en) | 2011-07-29 | 2014-03-24 | Univ Pennsylvania | Switch costimulatory receptors |
| US9688740B2 (en) * | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| EP4541818A3 (en) * | 2012-05-25 | 2025-07-23 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| EP3763810A3 (en) * | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| BR112015020516A2 (pt) * | 2013-02-26 | 2017-10-10 | Memorial Sloan Kettering Cancer Center | composições e métodos para imunoterapia |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US10047137B2 (en) | 2013-04-05 | 2018-08-14 | Versitech Limited | Antibodies against novel PD1 isoforms and uses thereof |
| KR102164455B1 (ko) | 2013-05-08 | 2020-10-13 | 삼성전자주식회사 | 콘텐트 제공 방법, 콘텐트 제공 장치 및 그 콘텐트 제공 시스템 |
| EP2994530A4 (en) * | 2013-05-10 | 2016-11-16 | Whitehead Biomedical Inst | PROTEIN MODIFYING LIVING CELLS USING SORTASE |
| US20170081411A1 (en) | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| PL3177640T3 (pl) * | 2014-08-08 | 2020-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania |
| KR102133857B1 (ko) * | 2015-03-02 | 2020-07-20 | 이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드 | Ｐｄ－ｌ１에 의해 유도된 면역관용의 감소 |
| US10493139B2 (en) | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
| US11242375B2 (en) | 2015-09-04 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
| US11648268B2 (en) | 2015-12-09 | 2023-05-16 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| US20220265708A1 (en) | 2018-01-11 | 2022-08-25 | Innovative Cellular Therapeutics, Inc. | Modified Cell Expansion and Uses Thereof |
| US20210379149A1 (en) | 2018-10-25 | 2021-12-09 | Innovative Cellular Therapeutics Holdings, Ltd. | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy |
-
2016
- 2016-03-01 KR KR1020177027722A patent/KR102133857B1/ko not_active Expired - Fee Related
- 2016-03-01 CN CN201810281004.XA patent/CN108410892B/zh active Active
- 2016-03-01 BR BR112017018770-1A patent/BR112017018770A2/pt not_active Application Discontinuation
- 2016-03-01 JP JP2017546893A patent/JP6336684B2/ja active Active
- 2016-03-01 CN CN201680002926.1A patent/CN107073138B/zh active Active
- 2016-03-01 AU AU2016228080A patent/AU2016228080B2/en not_active Ceased
- 2016-03-01 RU RU2017130985A patent/RU2688692C2/ru active
- 2016-03-01 SG SG11201706947TA patent/SG11201706947TA/en unknown
- 2016-03-01 EP EP19172425.1A patent/EP3549612B1/en active Active
- 2016-03-01 EP EP16717825.0A patent/EP3089761B1/en active Active
- 2016-03-01 WO PCT/CN2016/075061 patent/WO2016138846A1/en not_active Ceased
- 2016-03-01 CA CA2976684A patent/CA2976684C/en active Active
- 2016-04-07 US US15/093,643 patent/US9572837B2/en active Active
- 2016-12-08 US US15/373,012 patent/US10619136B2/en active Active
-
2017
- 2017-11-21 JP JP2017223489A patent/JP6767347B2/ja active Active
-
2019
- 2019-05-06 US US16/404,349 patent/US10865382B2/en active Active
-
2020
- 2020-11-23 US US17/101,780 patent/US11932873B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518037A5 (enExample) | ||
| RU2017130985A (ru) | Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека | |
| JP2016532693A5 (enExample) | ||
| JP2018508219A5 (enExample) | ||
| WO2018187613A3 (en) | Anti-icos agonist antibodies and uses thereof | |
| JP2015212284A5 (enExample) | ||
| JP2020114264A5 (enExample) | ||
| JP2018505139A5 (enExample) | ||
| JP2016502512A5 (enExample) | ||
| JP2020529841A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| HRP20240494T1 (hr) | Kimerni antigenski receptori specifični za bcma i njihove upotrebe | |
| JP2018518990A5 (enExample) | ||
| JP2019521643A5 (enExample) | ||
| JP2017522862A5 (enExample) | ||
| EP4424376A3 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| JP2018529327A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| NZ787244A (en) | ICOS ligand variant immunomodulatory proteins and uses thereof | |
| JP2019508444A5 (enExample) | ||
| WO2015104406A3 (en) | Multi-specific polypeptide useful for localized tumor immunomodulation | |
| ZA201607061B (en) | Transgene genetic tags and methods of use | |
| IL292650B2 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| JP2017537627A5 (enExample) |